Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)Sacha J. Howell, R. Charles Coombes, Simon Lord et al.|Cancer Research|2022Cited by 5